Alexion Pharmaceuticals Inc (ALXN) SEC Filing 10-K Annual report for the fiscal year ending Saturday, December 31, 2011

Earnings Press Release
10-K Annual Report
10-K YoY Changes
Alexion Pharmaceuticals, Inc.
Ticker: ALXN CIK: 899866

Exhibit 99.1

LOGO

Contacts:

Alexion Pharmaceuticals, Inc.

Irving Adler

Sr. Director, Corporate

Communications

(203) 271-8210

Alexion Pharmaceuticals, Inc.

Kimberly Diamond (Media)

Director, Corporate Communications

(203) 439-9600

Rx Communications (Investors)

Rhonda Chiger

(917) 322-2569

Alexion Reports Fourth Quarter and Full Year 2011 Results

- Soliris® (eculizumab) Net Product Sales Increased 45 Percent to $783 Million in 2011 -

- Continued Strong Uptake of Soliris by New PNH Patients; U.S. Launch in aHUS Begins -

- Pipeline Progresses with Five Compounds Targeting Severe and Ultra-Rare Disorders -

Fourth Quarter 2011 Financial Highlights:

•

Q4 2011 net product sales increased 46 percent to $227.6 million, compared to $156.0 million in Q4 2010.

•

Q4 2011 GAAP net income increased 82 percent, to $48.2 million, or $0.25 per share, compared to Q4 2010 GAAP net income of $26.5 million, or $0.14 per share.

•

Q4 2011 non-GAAP net income increased 65 percent to $80.5 million, or $0.41 per share, compared to Q4 2010 non-GAAP net income of $48.6 million, or $0.26 per share.

Full-Year 2011 Financial Highlights:

•

2011 net product sales increased 45 percent to $783.4 million, compared to $541.0 million in 2010.

•

2011 GAAP net income increased 81 percent to $175.3 million, or $0.91 per share, compared to 2010 GAAP net income of $97.0 million, or $0.52 per share.

The following information was filed by Alexion Pharmaceuticals, Inc. (ALXN) on Thursday, February 9, 2012 as an 8K 2.02 statement, which is an earnings press release pertaining to results of operations and financial condition. It may be helpful to assess the quality of management by comparing the information in the press release to the information in the accompanying 10-K Annual Report statement of earnings and operation as management may choose to highlight particular information in the press release.

View differences made from one year to another to evaluate Alexion Pharmaceuticals, Inc.'s financial trajectory

Compare SEC Filings Year-over-Year (YoY) and Quarter-over-Quarter (QoQ) — *Sample 10-K Year-over-Year (YoY) Comparison*

Compare this 10-K Annual Report to its predecessor by reading our highlights to see what text and tables were ~~removed~~ , added and changed by Alexion Pharmaceuticals, Inc..

Continue

Please wait while we load the requested 10-K report or click the link below:

https://last10k.com/sec-filings/report/899866/000144530512000363/alxn10k.htm